Champions Oncology, Inc. - Common Stock (CSBR)

Champions Oncology (NASDAQ:CSBR) reported record revenue for fiscal 2026 and positive adjusted EBITDA in every quarter of the year, supported by growth in its core Translational Oncology Solutions, or TOS, services business and efforts to bring radiopharmaceutical work in-house. For the fourth quar

Champions Oncology (CSBR) Earnings Transcript

This SaaS provider enables brands to personalize customer engagement across digital channels using data-driven orchestration tools.

This marketing technology provider delivers data-driven automation and consumer insights to enterprise clients across multiple channels.

Kodiak AI, Inc. delivers AI-powered navigation software for trucking, defense, and industrial fleets using proprietary sensor technology.

Sprinklr delivers a unified platform for enterprise customer experience management, serving global brands with integrated digital solutions.

Champions Oncology (CSBR) Earnings Call Transcript

Champions Oncology (CSBR) Earnings Transcript

Champions Oncology beats Q2 revenue estimates, returns to profit with record service revenue and expanding margins.

Champions Oncology posts record Q1 FY26 revenue of $14.0M but reports a wider-than-expected loss due to increased strategic investments in its data platform.

Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga's Edge Stock Rankings witnessing a significant decline.